Skip to Content
Merck
  • Developing structure-activity relationships for the prediction of hepatotoxicity.

Developing structure-activity relationships for the prediction of hepatotoxicity.

Chemical research in toxicology (2010-06-18)
Nigel Greene, Lilia Fisk, Russell T Naven, Reine R Note, Mukesh L Patel, Dennis J Pelletier
ABSTRACT

Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems. This process can be supported by the use of existing toxicity data and mechanistic understanding of the biological processes for related compounds. In the published literature, this information is often spread across diverse sources and can be varied and unstructured in quality and content. The current work has explored whether it is feasible to collect and use such data for the development of new SARs for the hepatotoxicity endpoint and expand upon the limited information currently available in this area. Reviews of hepatotoxicity data were used to build a structure-searchable database, which was analyzed to identify chemical classes associated with an adverse effect on the liver. Searches of the published literature were then undertaken to identify additional supporting evidence, and the resulting information was incorporated into the database. This collated information was evaluated and used to determine the scope of the SARs for each class identified. Data for over 1266 chemicals were collected, and SARs for 38 classes were developed. The SARs have been implemented as structural alerts using Derek for Windows (DfW), a knowledge-based expert system, to allow clearly supported and transparent predictions. An evaluation exercise performed using a customized DfW version 10 knowledge base demonstrated an overall concordance of 56% and specificity and sensitivity values of 73% and 46%, respectively. The approach taken demonstrates that SARs for complex endpoints can be derived from the published data for use in the in silico toxicity assessment of new compounds.

MATERIALS
Product Number
Brand
Product Description

Aflatoxin B1 solution, 3.79 μg/g in acetonitrile, ERM®, certified reference material
Supelco
Oxibendazole, VETRANAL®, analytical standard
Supelco
Betamethasone, VETRANAL®, analytical standard
Sigma-Aldrich
Carbendazim, 97%
Sigma-Aldrich
2,6-Diisopropylphenol, 97%
Sigma-Aldrich
(S)-(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, 98%
Sigma-Aldrich
L-Arginine, 99%, FCC, FG
Supelco
3-Methylcholanthrene, analytical standard
Supelco
3,5-Di-tert-butyl-4-hydroxytoluene, analytical standard
Supelco
Menadione (K3), analytical standard
Sigma-Aldrich
N-Acetyl-L-cysteine, Sigma Grade, ≥99% (TLC), powder
Sigma-Aldrich
Melatonin, powder, ≥98% (TLC)
Sigma-Aldrich
N-Acetyl-L-cysteine, BioXtra, ≥99% (TLC)
Sigma-Aldrich
Betaine hydrochloride, ≥99%
Sigma-Aldrich
5-Azacytidine, Hybri-Max, γ-irradiated, lyophilized powder, BioXtra, suitable for hybridoma
Sigma-Aldrich
Flurbiprofen, cyclooxygenase inhibitor
Sigma-Aldrich
N-Acetyl-L-cysteine, BioReagent, suitable for cell culture
Sigma-Aldrich
Acetaminophen, BioXtra, ≥99.0%
Sigma-Aldrich
2,6-Di-tert-butyl-4-methylphenol, ≥99.0% (GC), powder
Sigma-Aldrich
Ketoconazole, 99.0-101.0% (EP, titration)
Sigma-Aldrich
Ketoprofen, ≥98% (TLC)
Sigma-Aldrich
(±)-Chlorpheniramine maleate salt, ≥99% (perchloric acid titration)
Sigma-Aldrich
2′,3′-Dideoxycytidine, ≥98% (HPLC)
Sigma-Aldrich
5-Fluorocytosine, nucleoside analog
Sigma-Aldrich
Clofibrate, liquid
Sigma-Aldrich
Colchicine, ≥95% (HPLC), powder
Sigma-Aldrich
Terfenadine
Sigma-Aldrich
Sigma 7-9®, ≥99% (titration), crystalline
Sigma-Aldrich
Alloxan monohydrate, 98%
Supelco
Isoniazid, analytical standard, ≥99% (TLC)